Humana shares rise 5.3% as Medicare costs ease, but 2026 profit remains weak

Humana Inc. (NYSE: HUM) has raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share, compared with its previous expectation of at least $9, after reporting better-than-anticipated medical costs in the third quarter. The US health insurer recorded an insurance benefit ratio of 93.7%, below management’s expectation of slightly more than 94%, while individual Medicare Advantage membership increased approximately 23% during the first nine months. Shares gained approximately 5.3% on November 6, 2026, as investors welcomed the improved outlook.

The earnings announcement nevertheless presents a more complicated picture than the positive market reaction might suggest. Humana reported GAAP earnings of $1.33 per share for the third quarter, down from $1.62 a year earlier, while its adjusted result was a loss of $0.70 per share compared with adjusted earnings of $3.24 in the corresponding period of 2025. Although the medical cost ratio was better than anticipated, it remained substantially higher than the previous year’s level.

The results highlight the financial challenge facing Medicare Advantage insurers. Humana is attracting new members and expanding healthcare services, but the cost of providing medical benefits continues to place pressure on profitability. Management’s longer-term recovery strategy depends on improved insurance pricing, stronger quality ratings and operating efficiencies restoring margins over the next several years.

Why did Humana raise its earnings forecast despite reporting a quarterly adjusted loss?

Humana increased its annual adjusted earnings guidance to at least $9.50 per share after third-quarter medical costs proved more favourable than expected. The company reported a 93.7% insurance benefit ratio, compared with management’s earlier expectation of slightly above 94%. The difference indicates that medical benefit expenditure consumed a smaller share of relevant premium revenue than anticipated.

For a health insurer, the benefit ratio is a crucial measure because it reflects the proportion of premium revenue used to pay for members’ healthcare. A lower ratio generally improves underwriting profitability, assuming other factors remain unchanged. Even relatively small movements can have a substantial financial effect when applied to a large premium base.

However, the latest ratio remains elevated compared with the previous year. Humana’s medical benefit ratio was approximately 91.1% in the third quarter of 2025, meaning the 2026 figure increased by around 2.6 percentage points. The company is therefore experiencing better-than-expected costs rather than a year-on-year reduction in the proportion of premiums spent on medical care.

Humana’s consolidated quarterly revenue increased approximately 26% to $41.16 billion, reflecting substantial expansion of the business. Yet rapid revenue growth has not translated into equivalent earnings improvement because medical costs and other operating expenses are absorbing much of the increase. This divergence makes underwriting profitability more important than revenue growth alone.

Management expects medical and pharmacy cost trends to remain elevated, with the latest information suggesting performance in line with or better than its earlier high-single-digit assumptions. This provides some reassurance about the current year’s outlook, but the company must demonstrate that pricing and benefit changes can eventually offset the underlying cost environment.

How is Humana growing Medicare Advantage membership while competitors become more cautious?

Humana reported an increase of approximately 1.208 million individual Medicare Advantage members during the first nine months of 2026, representing growth of 23% from the end of 2025. The performance remains broadly aligned with management’s objective of increasing individual membership by approximately 25% over the full year. The company is therefore expanding at a substantial pace despite industry concerns over medical costs and reimbursement.

Medicare Advantage provides privately administered health coverage under the US Medicare programme. Insurers receive government payments to provide defined benefits, while financial performance depends on member risk characteristics, medical utilisation, administrative costs and the accuracy of pricing assumptions. Expanding membership can increase revenue, but new enrollees must ultimately generate sufficient premiums relative to their healthcare expenses.

Humana’s growth strategy has relied partly on changes to benefit design, customer service and retention. The company has sought to improve its appeal to customers while maintaining the infrastructure necessary to support a larger insured population. However, growing membership also increases exposure to unexpected medical costs if utilisation differs from forecasts.

The individual Medicare Advantage business is particularly important because Humana has committed to rebuilding profitability over a multiyear period. Management believes the larger membership base can support future earnings as pricing and reimbursement improvements take effect. Yet the financial contribution of new members depends on their actual medical expenditure, which may become clear only after claims data develop.

Humana’s Medicaid operations are also expanding. The company reported approximately 103,600 additional Medicaid members during the first nine months, representing 7% growth, largely supported by integrated programmes in Michigan, Illinois and South Carolina. This provides another avenue for revenue expansion, although Medicaid contracts have different reimbursement and regulatory characteristics from Medicare Advantage.

For investors, the combination of rapid membership growth and depressed margins creates a central question. Expanding the customer base may improve future profitability if unit economics recover, but it can also increase losses if premium rates fail to reflect healthcare costs adequately.

Why are Humana’s improved Medicare star ratings important for 2028 earnings?

Humana’s longer-term outlook has strengthened following a substantial improvement in Medicare Advantage quality ratings announced in October 2026. The company expects approximately 95% of its members to be enrolled in plans rated four stars or higher for the 2027 rating year. These ratings are important because they influence eligibility for government quality-bonus payments in subsequent periods.

The commercial benefit is not immediate. The 2027 ratings determine eligibility for quality-related payments in 2028, meaning the improvement will not automatically reverse current-year earnings pressure. The timing distinction is critical for understanding why Humana can report favourable quality developments while still forecasting substantially weaker 2026 earnings.

Management has indicated that the improved ratings, together with pricing and benefit changes, support its objective of achieving a pretax Medicare Advantage margin of at least 3% in 2028. That target represents a material improvement from the current profitability environment, but it remains dependent on medical cost trends, reimbursement policies and operational execution.

The quality-rating improvement also strengthens Humana’s competitive position. Higher-rated plans may benefit from enhanced payments and greater attractiveness to prospective members, depending on local market conditions and benefit design. However, financial outcomes still depend on how the additional revenue is allocated between member benefits, operating costs and profit.

Humana’s challenge is to translate quality improvements into sustainable margins rather than relying on bonus payments alone. Competitive pressure may encourage insurers to use some of the financial benefits to improve customer offerings, while medical inflation can absorb part of the additional revenue.

Investors should therefore evaluate the ratings development as an important future earnings catalyst, not a guarantee that the company’s 2028 financial objectives will be achieved.

How does Humana’s CenterWell expansion support its healthcare strategy?

Humana is expanding its CenterWell healthcare services operations alongside its insurance business. The company reported an increase of approximately 146,800 patients, or 30%, in CenterWell Senior Primary Care during the first nine months of 2026. The growth demonstrates management’s ambition to participate more directly in healthcare delivery rather than relying exclusively on insurance premiums.

The strategic rationale is that primary care and preventive services may help improve patient outcomes while managing the frequency and severity of expensive medical interventions. A healthcare organisation combining insurance and service delivery can potentially coordinate treatment and improve access to appropriate care. However, the financial benefits depend on clinical outcomes, patient characteristics and service-delivery costs.

CenterWell’s expansion also introduces operational risks. Opening and operating medical centres requires investment in clinicians, facilities, technology and patient services. Rapid growth can increase costs before newly established operations reach mature utilisation and profitability levels.

The company has announced a new strategic joint venture involving BlackRock-related investment capital to support CenterWell Senior Primary Care. The arrangement replaces the previous joint venture structure involving Welsh, Carson, Anderson & Stowe and is intended to improve financial flexibility and lower the cost of capital. The investment relationship may support further expansion without requiring Humana to finance every clinic directly from its own balance sheet.

However, joint-venture structures also involve accounting and ownership considerations. The arrangements can create valuation adjustments and changes in the allocation of future economic benefits. Investors should distinguish the capital provided through these structures from recurring operating earnings generated by the healthcare services business.

Humana’s integrated model could create long-term advantages if stronger primary care contributes to better health outcomes and more efficient healthcare spending. The company must nevertheless demonstrate that clinical expansion improves the economics of the broader business rather than simply increasing revenue and operating complexity.

Why is Humana’s GAAP earnings guidance much higher than its adjusted outlook?

Humana revised its full-year GAAP earnings guidance from at least $6.52 to at least $15.09 per share, a substantially larger increase than the change in adjusted guidance. The difference is primarily associated with accounting adjustments, including changes in the valuation of certain minority-interest investment arrangements. These items can materially affect reported earnings without representing equivalent improvements in recurring underwriting profitability.

The company’s third-quarter figures provide an illustration. GAAP earnings were $1.33 per share, while the adjusted result was a loss of $0.70 per share. The reconciliation included a negative $2.94 per-share adjustment related to put-and-call valuation changes associated with non-consolidated minority-interest investments, along with other adjustments and tax effects.

These measures serve different purposes. GAAP earnings reflect accounting requirements and recognised valuation effects, while adjusted earnings exclude specified items that management considers less representative of underlying operations. Neither measure should be evaluated in isolation, particularly when their movements diverge sharply.

The annual adjusted guidance also highlights how far Humana remains from its previous profitability level. The company’s 2025 adjusted earnings were $17.14 per share, compared with its new 2026 outlook of at least $9.50. At the guidance floor, this represents a decline of approximately 45%, despite the upward revision announced in November.

This comparison is more relevant to the operating turnaround than the large increase in GAAP guidance. It indicates that the company is still absorbing substantial pressure from medical costs, Medicare Advantage economics and quality-rating effects during 2026.

Investors should also consider the timing of expected earnings across the year. Humana reported adjusted earnings of $17.17 per share for the first nine months, already above its minimum full-year guidance. The relationship implies that management anticipates substantial fourth-quarter pressure under its current annual assumptions, reinforcing the importance of seasonality and the timing of medical expenses.

What should investors watch after Humana’s 5.3% share-price advance?

Humana shares finished the November 6 session at approximately $433.7, up around 5.3%, after trading as high as approximately $444. The positive reaction reflects relief that medical cost trends were better than expected and that management was able to raise annual guidance. However, the share-price response does not establish that the insurer has returned to its historical profitability.

The next critical indicators will be the insurance benefit ratio, Medicare Advantage membership trends and the financial impact of benefit changes implemented for 2027. Investors will also monitor CenterWell’s operating costs, Medicaid expansion and the eventual contribution of improved star ratings to reimbursement.

The company’s stated objective of achieving a pretax Medicare Advantage margin of at least 3% in 2028 provides a measurable benchmark. Progress will depend on the relationship between premium revenue and medical costs, quality bonuses and the operating efficiency of its healthcare services. A more profitable membership base would provide stronger evidence of recovery than membership growth alone.

Humana’s November results indicate that operational performance is improving relative to management’s expectations. Nevertheless, the gap between current adjusted earnings and the previous year’s profitability demonstrates the scale of the remaining challenge.

The company’s long-term opportunity is substantial because of its Medicare Advantage position and expanding healthcare services network. However, sustained shareholder value will depend on converting membership growth and quality improvements into dependable operating margins.

The immediate earnings upgrade is encouraging, but the more consequential question is whether Humana can deliver the promised recovery in 2027 and 2028 while maintaining medical cost discipline and competitive customer offerings.